ALNY

329.35

2.03% -6.84

Dopo l'orario di chiusura: 330.76 1.41 +0.43%

Alnylam Pharmaceuticals Inc (ALNY)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ALNY Giù? Forum Previsione

Precedente Chiudi:

$336.19

Aprire:

$335.73

Volume 24 ore:

787.34K

Relative Volume:

0.53

Capitalizzazione di mercato:

$43.68B

Reddito:

$3.71B

Utile/perdita netta:

$313.75M

Rapporto P/E:

145.92

EPS:

2.2571

Flusso di cassa netto:

$465.38M

1 W Prestazione:

+4.76%

1M Prestazione:

-8.00%

6M Prestazione:

-27.52%

1 anno Prestazione:

+31.43%

Intervallo 1D:

$326.76

$341.38

Intervallo di 1 settimana:

$315.62

$345.89

Portata 52W:

$205.87

$495.55

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Nome

Alnylam Pharmaceuticals Inc

Settore

Healthcare (1110)

Industria

Biotechnology (622)

Telefono

(617) 551-8200

Indirizzo

675 WEST KENDALL STREET, CAMBRIDGE, MA

Dipendente

2,500

Cinguettio

@alnylam

Prossima data di guadagno

2026-02-12

Ultimi documenti SEC

ALNY's Discussions on Twitter

Compare ALNY vs VRTX, REGN, ARGX, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ALNY Alnylam Pharmaceuticals Inc	329.35	44.59B	3.71B	313.75M	465.38M	2.2571
VRTX Vertex Pharmaceuticals Inc	481.01	121.15B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	787.04	82.43B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	826.25	52.25B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	370.64	40.07B	4.98B	69.60M	525.67M	0.5198

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-01-28	Ripresa	Barclays	Overweight
2026-01-07	Ripresa	Oppenheimer	Outperform
2025-08-04	Aggiornamento	Oppenheimer	Perform → Outperform
2025-08-04	Aggiornamento	Wolfe Research	Underperform → Peer Perform
2025-07-30	Ripresa	Raymond James	Outperform
2025-07-21	Iniziato	Truist	Buy
2025-03-31	Iniziato	Redburn Atlantic	Buy
2025-03-24	Aggiornamento	JP Morgan	Neutral → Overweight
2024-11-12	Downgrade	Wolfe Research	Peer Perform → Underperform
2024-10-16	Iniziato	Scotiabank	Sector Outperform
2024-08-16	Aggiornamento	Goldman	Neutral → Buy
2024-02-16	Downgrade	Goldman	Buy → Neutral
2024-02-15	Iniziato	Wolfe Research	Peer Perform
2023-12-08	Iniziato	Wells Fargo	Equal Weight
2023-10-11	Downgrade	Oppenheimer	Outperform → Perform
2023-09-29	Iniziato	Raymond James	Outperform
2023-05-05	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2023-04-26	Iniziato	SMBC Nikko	Neutral
2023-03-21	Iniziato	Bernstein	Outperform
2023-01-18	Iniziato	Canaccord Genuity	Buy
2022-09-09	Ripresa	Morgan Stanley	Equal-Weight
2022-07-13	Iniziato	Cantor Fitzgerald	Neutral
2022-06-27	Downgrade	Guggenheim	Buy → Neutral
2022-06-07	Iniziato	William Blair	Outperform
2022-04-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2022-03-01	Iniziato	Citigroup	Buy
2022-02-03	Aggiornamento	Guggenheim	Neutral → Buy
2022-01-03	Aggiornamento	Piper Sandler	Neutral → Overweight
2021-11-22	Aggiornamento	Goldman	Neutral → Buy
2021-11-22	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2021-11-01	Aggiornamento	Oppenheimer	Perform → Outperform
2021-10-04	Aggiornamento	UBS	Neutral → Buy
2021-08-04	Downgrade	Piper Sandler	Overweight → Neutral
2021-02-22	Downgrade	Guggenheim	Buy → Neutral
2021-02-12	Downgrade	Citigroup	Buy → Neutral
2021-02-12	Reiterato	H.C. Wainwright	Buy
2021-01-25	Downgrade	BMO Capital Markets	Outperform → Market Perform
2020-09-30	Ripresa	Berenberg	Hold
2020-09-08	Iniziato	Citigroup	Buy
2020-08-11	Downgrade	Oppenheimer	Outperform → Perform
2020-05-13	Iniziato	RBC Capital Mkts	Sector Perform
2020-05-07	Downgrade	JP Morgan	Overweight → Neutral
2020-04-24	Ripresa	Evercore ISI	Outperform
2020-03-19	Iniziato	Berenberg	Buy
2019-12-19	Reiterato	Chardan Capital Markets	Buy
2019-11-20	Iniziato	Oppenheimer	Outperform
2019-11-13	Iniziato	BofA/Merrill	Buy
2019-05-23	Ripresa	Goldman	Neutral
2019-04-12	Iniziato	Evercore ISI	Outperform
2019-03-06	Aggiornamento	Evercore ISI	In-line → Outperform
2019-03-05	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2019-01-23	Iniziato	UBS	Neutral
2018-10-01	Iniziato	Cantor Fitzgerald	Overweight
2018-08-13	Reiterato	Stifel	Buy
2018-08-07	Aggiornamento	Stifel	Hold → Buy
2018-05-04	Reiterato	Stifel	Hold
2018-03-28	Iniziato	Evercore ISI	In-line

Mostra tutto

Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie

10:00 AM

Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference - Yahoo Finance

10:00 AM

Feb 22, 2026

Understanding the Setup: (ALNY) and Scalable Risk - Stock Traders Daily

Feb 22, 2026

Feb 21, 2026

Fiera Capital Corp Grows Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Feb 21, 2026

NewEdge Wealth LLC Buys 7,091 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Feb 21, 2026

ANTIPODES PARTNERS Ltd Cuts Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Feb 21, 2026

Feb 20, 2026

Will Alnylam Pharmaceuticals Inc. stock benefit from automationTrade Risk Summary & High Return Stock Watch Alerts - mfd.ru

Feb 20, 2026

China Universal Asset Management Co. Ltd. Cuts Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Feb 20, 2026

Alnylam Pharmaceuticals (ALNY) Reports $3B 2025 Revenue Driven by 151% TTR Franchise Surge - Insider Monkey

Feb 20, 2026

Feb 19, 2026

Assessing Alnylam Pharmaceuticals (ALNY) Valuation After First Profitable Year And Rapid Revenue Growth - simplywall.st

Feb 19, 2026

Analysts Offer Insights on Healthcare Companies: Moderna (MRNA) and Alnylam Pharma (ALNY) - The Globe and Mail

Feb 19, 2026

Shifting Trends in Biotechnology Mergers and Acquisitions - Intellectia AI

Feb 19, 2026

Regeneron Pharmaceuticals Inc. Lowers Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Feb 19, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Upgraded by Freedom Capital - MarketBeat

Feb 19, 2026

Oligonucleotide Therapy Market to hit US$ 40.16 Billion by 2033 | - openPR.com

Feb 19, 2026

RNAi Therapeutics Market to hit US$ 8.80 Billion by 2033 | North - openPR.com

Feb 19, 2026

11,700 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Bought by Alberta Investment Management Corp - MarketBeat

Feb 19, 2026

1 Reason I'd Buy Eli Lilly Stock and Never Sell - AOL.com

Feb 19, 2026

How Alnylam (NASDAQ:ALNY) Is Reframing Nasdaq Index Fund Allocation Trends - Kalkine Media

Feb 19, 2026

Analysts Trim Alnylam Pharmaceuticals, Inc. (ALNY) Targets but Keep Faith in 2026 Growth - Finviz

Feb 19, 2026

Feb 18, 2026

Alnylam Pharmaceuticals' (ALNY) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Feb 18, 2026

HC Wainwright Reiterates Buy Rating on ALNY with Price Target at $510 | ALNY Stock News - GuruFocus

Feb 18, 2026

Insider Unloading: Jeffrey V Poulton Sells $695K Worth Of Alnylam Pharmaceuticals Shares - Benzinga

Feb 18, 2026

EVP Of Alnylam Pharmaceuticals Makes $607K Sale - Benzinga

Feb 18, 2026

Sell Alert: Yvonne Greenstreet Cashes Out $2.16M In Alnylam Pharmaceuticals Stock - Benzinga

Feb 18, 2026

Inflation Data: Whats the beta of Alnylam Pharmaceuticals Inc stockM&A Rumor & Verified Short-Term Trading Plans - baoquankhu1.vn

Feb 18, 2026